Pharmaxis Ltd


Pharmaxis Ltd (ASX:PXS) (OTCMKTS:PXSLY) (ACN 082 811 630) is an Australian research pharmaceutical company focused on inflammation and fibrosis with a portfolio of products at various stages of development and approval. Its product Bronchitol® for cystic fibrosis is marketed in Europe, Russia and Australia. Its product Aridol® for the assessment of asthma is sold in Europe, Australia and Asia.

The company’s development pipeline is centred on its expertise in amine oxidase chemistry and includes a series of Lysyl Oxidase Inhibitors that will enter clinical development in 2017 targeting fibrotic diseases of the heart, kidney, liver and lung. In May 2015, Boehringer Ingelheim acquired the Pharmaxis investigational drug PXS-4728A, a potent inhibitor of Semicarbazide-Sensitive Amine Oxidase (SSAO), to develop it for the treatment of the liver-related condition Non-alcoholic Steatohepatitis (NASH) and other inflammatory diseases.

Pharmaxis is listed on the Australian Securities Exchange (symbol PXS). The company’s head office, manufacturing and research facilities are located in Sydney, Australia. For more information about Pharmaxis, please see


View in Other Languages


BTC Health Limited (ASX:BTC) Acquires Exclusive Distribution Rights for Bronchitol(R) and Aridol(R) from Pharmaxis

🕔7/6/2021 10:44:41 AM 27488

BTC Health Limited (ASX:BTC) is pleased to announce its investee company, BioImpact Pty Ltd, has acquired exclusive distribution rights for specialty respiratory brands Bronchitol(R) and Aridol(R) from Pharmaxis (ASX:PXS) in Australia, New Zealand, Singapore, Malaysia, Hong Kong and South Korea (Bronchitol(R) only).

Read Full Article

Pharmaxis Ltd (ASX:PXS) Boehringer Ingelheim is Initiating Phase IIa Study for the Development of a New Treatment for Diabetic Retinopathy - a Leading Cause of Vision-Loss

🕔9/8/2017 1:38:29 PM 6610

Boehringer Ingelheim and pharmaceutical research company Pharmaxis (ASX:PXS) (OTCMKTS:PXSLY) announce that Boehringer Ingelheim is initiating the Phase IIa study ROBIN. This marks the beginning of the clinical development program for BI 1467335 in a second indication targeting a severe diabetes complication. An already ongoing Phase II clinical study program is investigating the compound in NASH.

Read Full Article

Boehringer Ingelheim Initiates Phase IIa Study of Compound Acquired from Pharmaxis Ltd (ASX:PXS) in Debilitating Liver Disease NASH

🕔9/8/2017 12:01:53 PM 6072

Boehringer Ingelheim and pharmaceutical company Pharmaxis (ASX:PXS) (OTCMKTS:PXSLY) announce that Boehringer Ingelheim has initiated a European and North American Phase IIa trial in NASH with BI 1467335 (formerly known as PXS-4728A), acquired from Pharmaxis in May 2015.

Read Full Article

Biotech Investors Move Ahead on the Learning Curve

🕔6/11/2015 3:13:43 PM 12297

Australian and New Zealand biotech investors are set to hear from a top line up of speakers from ASX-listed life science companies, as well as several private firms and international businesses, in July, at the 11th Bioshares Biotech Summit.

Read Full Article

Australian Market Report of February 8, 2011: Robust Resources (ASX:ROL) Discover High Grade Gold, Silver And Sulphide Mineralisation in Indonesia

🕔2/8/2011 1:30:00 PM 13942

Australian Market Report of February 8, 2011 includes: Robust Resources Limited (ASX:ROL) has intersected near-surface high grade gold, silver and sulphide mineralisation in East Indonesia; Pharmaxis Limited (ASX:PXS) received approval for marketing Bronchitol in Australia to treat cystic fibrosis; St George Mining Limited (ASX:SGQ) announced new gold targets in Western Australia; Jatoil Limited (ASX:JAT) signed a deal to acquire coal assets in Queensland.

Read Full Article

Australian Market Report of December 13, 2010: Altura Mining (ASX:AJM) Received Approval for Lithium Drill Program in WA

🕔12/13/2010 1:30:00 PM 10842

Australian Market Report of December 13, 2010 includes: Altura Mining Limited (ASX:AJM) has received approval for the upcoming drill program at Pilgangoora Lithium Project in WA; Orion Metals Limited (ASX:ORM) has received highly encouraging gold results at Killi Killi Hills Gold-Rare Earth Element Project; Pharmaxis Limited (ASX:PXS) announces that Bronchitol is recommended for approval By Australian Advisory Committee; Tabcorp Holdings Limited (ASX:TAH) proposed A$625 million expansion of its casinos in Queensland.

Read Full Article

Pharmaxis confirms ADR position and deposits with the Bank Of New York

🕔11/10/2005 4:11:01 PM 7232

Pharmaxis (ASX: PXS) is undertaking a public offering of ordinary shares in the form of American Depositary Shares in the United States.

Read Full Article

Pharmaxis Ltd Announces Pricing of Global Capital Raising

🕔11/8/2005 3:15:54 PM 6394

Pharmaxis Ltd (ASX: PXS) announced today the pricing of an underwritten public offering of 1,300,000 American Depositary Shares at a price of USD$24.16 per ADS. Each ADS represents 15 ordinary shares in Pharmaxis. CIBC World Markets Corp. acted as sole book-running manager of the offering.

Read Full Article


  • This Page Viewed: (Last 7 Days: 16) (Last 30 Days: 85) (Since Published: 13953) 

Company Data

  • (02) 9451 3622 
  • Principal Sector
  • Health & Pharm 
  • Principal Industry
  • Biotechnology 
  • Listed
  • 2003/11/10 
  • Homepage